A list of recent research advances in cell journal for the new coronavirus SARS-CoV-2/COVID-19 (No. 5)

Initially, scientists isolated nearly 600 different antibodies from the blood of people who beat COVID-19.
laboratory tests, they were able to narrow down to several antibodies that were particularly effective in binding to the virus.
, they used cell cultures to artificially create these antibodies.
crystallological analysis showed that these identified so-called meso-antibodies bind to the virus, preventing it from entering cells and proliferating.
addition, antibodies' recognition of the virus helps immune cells eliminate it. Dr. Jakob Kreye of the German Center for Neurodegenerative Diseases, co-lead author of the
paper, said the study of hamsters, who, like humans, were susceptible to SARS-CoV-2 infection, confirmed the effectiveness of the antibodies chosen: "If these antibodies were given after infection, hamsters would have mild symptoms of disease at most."
if these antibodies were given before infection, hamster animals would not get sick.
"3.Cell: Using interactive, experiantive real-life simulation programs to prevent outbreaks doi:10.1016/j.cell.2020.08.0422 In 2015, a team of disease outbreak modeling experts and educators created Opera Outbreak, an educational platform and simulation program designed to teach high school and college students the basics of coping with pandemics.
the program, which is open source and free of charge, is designed to simulate disease outbreaks with different variables, such as R0 and transmission patterns, and generate data in the context of real human behavior.
includes a Bluetooth-based app that tracks contacts by recording transmission events between phones.
recently, cell magazine published an opinion piece entitled "Preventing outbreaks through interactive, experiential real-life simulations", highlighting these details.
this summer, as the COVID-19 pandemic continued to spread, Operation Outbreak was rolled out to 2,000 students in Chicago who participated in the One Summer Chicago program as "social isolation ambassadors."
participants used the app to track and track behavior to understand how "infections" spread in different parts of the city.
4.Cell: Clinical studies have confirmed that vaccination of card-mediated seedlings reduces respiratory infections in older adults by 75%: 10.1016/j.cell.2020.08.051-card-mediated seedlings (BCG vaccine) have a wide range of stimulating effects on the immune system.
makes it effective in preventing infections -- and possibly coVID-19.
new research is investigating this.
card seedlings are often used in children, but in a new double-blind randomized clinical study calledACTIVATE, researchers from research institutions such as Radburg University Medical Center in the Netherlands and the University of Athens in Greece have found that older people can also benefit from card-based seedlings.
results were published online August 31, 2020 in the journal Cell, under the title "ACTIVATE: Randomized clinical trial of BCG ingest in the oldly."
images from CC0 Public Domain.
at Radburg University Medical Center, Mihai Netea, a professor of experimental medicine, is studying the protective effects of card-based seedlings on a variety of infections, known as "trained immunity."
Two years ago, we started the ACTATE study to see if vaccinations protect vulnerable older people from infection, " says Professor Netea.
65-year-olds were randomly vaccinated with a card seedling or placebo upon discharge.
we followed them for a year to see if the card-like seedlings could protect them from a wide range of infections.
"5.Cell: Animal Studies Find Small Antibodies Effective in Treating and Preventing New Coronavirus Infections Doi:10.1016/j.cell.2020.09.007 In a new study, the University of Pittsburgh, USA Researchers at the School of Medicine, the University of North Carolina at Chapel Hill, the Galveston Medical Division of the University of Texas, the University of British Columbia in Canada and the University of Saskatchewan analyzed the smallest antibody molecules to date that can be fully and specifically neutral with SARS-CoV-2 coronavirus.
tiny antibody molecule, which is 10 times smaller than full-size antibodies, has been used to build a drug called Ab8 that has the potential to treat and prevent SARS-CoV-2 infections.
study was recently published in the Journal of Cell under the title "High Potency of a Bivalent Human VH Domain in SARS-CoV-2 Animal Models".
the researchers reported that Ab8 is very effective in preventing and treating SARS-CoV-2 infections in mice and hamsters.
its tiny size not only increases its potential to spread in tissues to better contain the coronavirus, but also makes it possible to do so through alternative routes such as inhalation.
important, it doesn't bind to human cells--- which is a good sign that it doesn't have side effects on people.
, co-author of the study and director of the Infectious Diseases Section at the University of Pittsburgh School of Medicine, said, "Ab8 not only has the potential to treat COVID-19, but may also be used to prevent people from contracting SARS-CoV-2.
larger antibodies are already effective against other infectious diseases and are well-resistant, which gives us hope that Ab8 may be effective in treating COVID-19 patients and may also protect people who have never been infected and have no immunity.
"6.Cell review is compiled in full! It is pointed out that the new coronavirus may inhibit the long-acting antibody response, but it is still possible to achieve immune memory doi:10.1016/j.cell.2020.09.013 Current limited data show that SARS-CoV-2 can induce a certain degree of immunity.
so far, there has been only one clear report of re-infection within four months confirmed by viral gene sequencing, and in a small study, the Ganges.